Drug overdoses see major decline – except in these 2 states
(NEXSTAR) – After years of alarming increases, fatal drug overdoses have finally dropped in America, the Centers for Disease Control and Prevention announced.
The agency reported there were 30,000 fewer deaths from drug overdoses in 2024 than there were the year prior. It's the largest one-year decline ever recorded – about 27% – but nonetheless, around 80,000 people lost their lives to an overdose.
The biggest drops were in some of the states hardest hit by the opioid overdose epidemic, including West Virginia, which saw a 44% single-year decline.
Virginia, D.C., Wisconsin, New Hampshire, Michigan, Ohio, and Louisiana all saw drops of more than 35%.
Two states, Nevada and South Dakota, were outliers. Those states actually recorded an increase in fatal overdoses in 2024.
South Dakota's overall numbers are still quite small, however. The state recorded 88 overdose deaths last year. States with much larger populations, like California, Florida and Texas, reported between about 5,000 and 10,000.
The CDC notes this data is provisional and incomplete. In many cases, the cause of death could still be under investigation, and so the final death toll could differ.
Experts say more research needs to be done to understand what drove the reduction, but they mention several possible factors. Among the most cited:
Still, annual overdose deaths are higher than they were before the COVID-19 pandemic. In a statement, the CDC noted that overdoses are still the leading cause of death for people 18-44 years old, 'underscoring the need for ongoing efforts to maintain this progress.'
Some experts worry that the recent decline could be slowed or stopped by reductions in federal funding and the public health workforce, or a shift away from the strategies that seem to be working.
'Now is not the time to take the foot off the gas pedal,' said Dr. Daniel Ciccarone, a drug policy expert at the University of California, San Francisco.
The Associated Press contributed to this report.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
31 minutes ago
- Medscape
Fast Five Quiz: Opioid Use Disorder
Opioid use disorder (OUD) currently impacts approximately 16 million people worldwide. It is considered a significant public health issue, with experts noting a 'burden that is increasing' globally. As research into optimal management of OUD evolves, updates to clinical guidelines emphasize a more individualized approach to pharmacologic treatment, psychosocial support, and special considerations for specific patient populations, such as pregnant individuals. However, OUD remains a complex disease that comes with many serious health and legal concerns for both patients and clinicians. What do you know about OUD? Check your knowledge with this quick quiz. Despite pharmacologic treatment being known to be highly effective for treating OUD, a CDC report states that 30% of patients with OUD who require OUD treatment received only nonpharmacologic treatment. Further, 43% of patients did not perceive a need for OUD treatment at all. In this significant report, males aged 35-49 years were most likely to receive OUD treatment with medications, while females and younger and older adults had lower rates of access to pharmacologic interventions. The CDC concluded that engaging patients needing OUD treatment with pharmacologic interventions is 'essential.' Learn more about essential statistics for OUD. Data from a predictive-model study indicate that service setting was the strongest predictor for premature discontinuation of OUD treatment. The strength of this predictor declined with length of stay, becoming negligent after 365 days. Other system-level factors such as geographic region, primary source of payment for treatment, and referral source were also strong predictors of early discontinuation; individual factors such as age of first use, sex, and race were less predictive. Previous research cited by the study has also stressed the importance of reducing system-level barriers to care, and the updated federal guidance for opioid treatment programs have expanded access in several ways. Learn more about OUD guidance. Precipitated withdrawal can occur when transferring a patient from methadone to buprenorphine due to buprenorphine being only a partial opioid agonist; as such, the traditional method of transfer involves putting the patient in a controlled, moderate withdrawal state before initiating buprenorphine therapy. However, a novel dosing strategy called microinduction, which involves starting buprenorphine at submilligram doses (or 'low-dose induction'), and cross-tapering with methadone can prevent precipitated withdrawal. Additionally, this method is ideal for patients who want to switch from methadone to buprenorphine and those with chronic use of intravenous or intranasal fentanyl. A recent systematic review found that microinduction and traditional transfer methods had similar rates of successful induction of buprenorphine at 95.6%. Learn more about safe withdrawal practices for OUD. Both the CDC and the latest American Society of Addiction Medicine (ASAM) guidelines specifically state that pharmacotherapy for OUD should be offered as early as possible in pregnancy to prevent harms to both the patient and the fetus, noting that pharmacotherapy for OUD has been associated with improved maternal outcomes. ASAM specifically states, 'increasing the dose or split dosing is often required, especially in the third trimester.' Federal guidelines emphasize that pregnant individuals seeking treatment for OUD are considered a priority for enrollment in opioid treatment programs. Once receiving treatment, they do not generally recommended medically supervised withdrawal from pharmacotherapy for pregnant patients as it might harm the fetus and patient; further, ASAM guidelines state that patients who undergo medically supervised withdrawal are at an increased risk for 'return to opioid use.' However, if a patient decides to proceed with medically supervised withdrawal, ASAM guidelines suggest physicians provide education and resources regarding associated risks. The CDC also specifically recommends against abruptly discontinuing opioids during pregnancy, citing data and resources from the American College of Obstetricians and Gynecologists and the Substance Abuse and Mental Health Services Administration. Learn more about OUD. Federal guidelines specify that opioid treatment programs must conduct at least eight random drug tests per year on their patients. These tests must use FDA approved products that test for commonly abused substances that might affect patient safety, recovery, or adherence to OUD treatment. ASAM affirms this requirement, noting that many patients might need more frequent testing and that eight tests per year 'should be viewed as a minimum.' Learn more about drug testing in OUD. Editor's Note: This article was created using several editorial tools, including generative AI models, as part of the process. Human review and editing of this content were performed prior to publication.
Yahoo
an hour ago
- Yahoo
RFK Jr.'s newest CDC vaccine panel includes critics of COVID shots, lockdowns
The Brief U.S. Health Secretary Robert F. Kennedy Jr. has replaced the government's vaccine advisory panel with eight new appointees. The new members include vocal critics of COVID-19 vaccines and pandemic lockdowns, such as Dr. Robert Malone and Dr. Martin Kulldorff. Public health groups have raised concerns that Kennedy's changes could undermine long-standing vaccination policies. NEW YORK - U.S. Health Secretary Robert F. Kennedy Jr. has named eight new vaccine policy advisers to replace the panel that he abruptly dismissed earlier this week. His selections include a scientist who researched mRNA vaccine technology and transformed into a conservative darling for his criticisms of COVID-19 vaccines, and a leading critic of pandemic-era lockdowns. RELATED: RFK Jr. ousts entire CDC vaccine panel Kennedy made the announcement in a social media post on Wednesday. The backstory Kennedy's decision to "retire" the previous 17-member panel was widely decried by doctors' groups and public health organizations, who feared the advisers would be replaced by a group aligned with Kennedy's desire to reassess — and possibly end — longstanding vaccination recommendations. Dig deeper The new appointees to the Advisory Committee on Immunization Practices include Dr. Robert Malone, the former mRNA researcher who emerged as a close adviser to Kennedy during the measles outbreak. Malone, who runs a wellness institute and a popular blog, rose to popularity during the COVID-19 pandemic as he relayed conspiracy theories around the outbreak and the vaccines that followed. He has appeared on podcasts and other conservative news outlets where he's promoted unproven and alternative treatments for measles and COVID-19. He has claimed that millions of Americans were hypnotized into taking the COVID-19 shots. He's even suggested that those vaccines cause a form of AIDS. He's downplayed deaths related to one of the largest measles outbreaks in the U.S. in years. Other appointees include Dr. Martin Kulldorff, a biostatistician and epidemiologist who was a co-author of the Great Barrington Declaration, an October 2020 letter maintaining that pandemic shutdowns were causing irreparable harm. Dr. Cody Meissner, a former ACIP member, also was named. Big picture view The committee, created in 1964, makes recommendations to the director of the Centers for Disease Control and Prevention. CDC directors almost always approve those recommendations on how Food and Drug Administration-cleared vaccines should be used. The CDC's final recommendations are widely heeded by doctors and determine the scope of vaccination programs. The Source The Associated Press contributed to this report. The information in this story comes from a social media announcement made by U.S. Health Secretary Robert F. Kennedy Jr. on Wednesday, in which he introduced eight new members to the federal vaccine advisory panel. This story was reported from Los Angeles.
Yahoo
an hour ago
- Yahoo
Matthew 25 unveils mobile STD testing unit
HENDERSON, Ky (WEHT) – The non-profit organization Matthew 25 held a ribbon cutting to celebrate its campaign to help prevent, educate and treat people in the Tri-State with Sexual Transmitted Diseases. Last August, The Centers for Disease Control and Prevention granted $3,000,000 in funding to the organization. Matthew 25 used a large portion of that grant in partnership with Mission Mobile Medical to customize the treatment center. As for why this was needed, Chief Executive Officer, Courtney Woolfork, said, 'We have clinics in Owensboro, Henderson, and Bowling Green. But everything in between is really hard for people to get access to, because there isn't public transportation always.' The non-profit covers 25 counties in Kentucky and 12 in Indiana and officials say that they have seen STD trends increasing in those regions. Woolfork says that trends like these are why it's so beneficial to have a mobile treatment unit that can serve vulnerable areas. The mobile unit will also have PREP pills available to those who have had a Sexually Transmitted Illnesses. Matthew 25 urges those who have come in contact with an STD or STI to get this pill to lessen their chances of contracting HIV in the future. Over the next couple months, Woolfork and her team plan on traveling to 25 counties in the Tri-State. March 27 will kick off the road trip, as they will be in Owensboro, Kentucky for National HIV Testing Day. Although they are fighting an uphill battle the mission statement is clear, 'Meeting people where they are and however they are.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
